Systematic Reviews| Volume 217, ISSUE 2, P150-166, August 2017

Download started.


The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis

Published:February 23, 2017DOI:


      Premenstrual syndrome is characterized by the cyclic occurrence of physical, behavioral and psychological symptoms during the luteal phase of the menstrual cycle disappearing within a few days of the onset of menstruation. Generally symptoms are mild, but 5–8% of women suffer from severe PMS. Apart from conventional drugs, like serotonin reuptake inhibitors and oral contraceptives, complementary and alternative medicines such as Vitex agnus castus are used by many women experiencing PMS.


      Our objective was to determine the efficacy, tolerability, and acceptability of Vitex agnus castus preparations for treatment of premenstrual syndrome.

      Study Design

      All journals in the Ovid software from inception through January 2016 were searched, including the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, and PsycINFO. Gray literature was searched by Google Scholar and manufacturers of Vitex agnus castus preparations were contacted for information about unpublished trials. We included randomized controlled trials with Vitex agnus castus in women with premenstrual syndrome and/or premenstrual dysphoric disorder with a minimal duration of 2 menstrual cycles. The eligibility of the manuscripts was assessed by 2 reviewers independently. The data abstracted included characteristics of the study design, characteristics of the patient population, intervention details, type of comparator, method of diagnosis, and outcome measures. We adhered to the PRISMA guidelines.


      We found 17 randomized controlled trials of Vitex agnus castus in the treatment of premenstrual syndrome. Fourteen of these could be included in the quantitative analysis. Thirteen of 14 studies with placebo, dietary supplements, or herbal preparations as controls reported positive effects of Vitex agnus castus on total premenstrual syndrome symptoms. Unfortunately most of the trials are associated with a high risk of bias. The pooled effect of Vitex agnus castus in placebo-controlled trials was large (Hedges g, –1.21; 95% confidence interval, –1.53 to –0.88), but heterogeneity was extremely high (I2, 91%). We were unable to single out factors that could explain this heterogeneity satisfactorily. The funnel plot and Egger tests suggest the presence of publication bias.


      Although meta-analysis shows a large pooled effect of Vitex agnus castus in placebo-controlled trials, the high risk of bias, high heterogeneity, and risk of publication bias of the included studies preclude a definitive conclusion. The pooled treatment effects should be viewed as merely explorative and, at best, overestimating the real treatment effect of Vitex agnus castus for premenstrual syndrome symptoms. There is a clear need for high-quality trials of appropriate size examining the effect of standardized extracts of Vitex agnus castus in comparison to placebo, selective serotonin reuptake inhibitors, and oral contraceptives to establish relative efficacy.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • O’Brien S.
        • Rapkin A.
        • Dennerstein L.
        • Nevatte T.
        Diagnosis and management of premenstrual disorders.
        BMJ. 2011; 342: d2944
        • Yonkers K.A.
        • O’Brien P.M.
        • Eriksson E.
        Premenstrual syndrome.
        Lancet. 2008; 371: 1200-1210
        • Beers M.H.
        • Porter R.S.
        • Jones T.V.
        • Kaplan J.L.
        • Berkwits M.
        Merck manual of diagnosis and therapy.
        18th ed. Merck Research Laboratories, Whitehouse Station (NJ)2006
        • American Psychiatric Association
        Diagnostic and statistical manual of mental disorders.
        5th ed. American Psychiatric Publishing, Arlington (VA)2013
      1. Association of Reproductive Health Professionals. A quick reference guide for clinicians. Managing premenstrual symptoms. Available at: Accessed Feb. 18, 2013.

        • Parry B.L.
        • Berga S.L.
        • Mostofi N.
        • Klauber M.R.
        • Resnick A.
        Plasma melatonin circadian rhythms during the menstrual cycle and after light therapy in premenstrual dysphoric disorder and normal control subjects.
        J Biol Rhythms. 1997; 12: 47-64
        • Shechter A.
        • Lespérance P.
        • Ng Ying Kin N.M.
        • Boivin D.B.
        Pilot investigation of the circadian plasma melatonin rhythm across the menstrual cycle in a small group of women with premenstrual dysphoric disorder.
        PLoS One. 2012; 7: e51929
        • Baller E.B.
        • Wei S.M.
        • Kohn P.D.
        • et al.
        Abnormalities of dorsolateral prefrontal function in women with premenstrual dysphoric disorder: a multimodal neuroimaging study.
        Am J Psychiatry. 2013; 170: 305-314
        • Wang A.C.
        • Hara Y.
        • Janssen J.G.
        • Rapp P.R.
        • Morrison J.H.
        Synaptic estrogen receptor-alpha-levels in prefrontal cortex in female rhesus monkeys and their correlation with cognitive performance.
        J Neurosci. 2010; 30: 12770-12776
        • Montague D.
        • Weickert C.S.
        • Tomaskovic-Crook E.
        • Rothmond D.A.
        • Kleinman J.E.
        • Rubinow D.R.
        Estrogen receptor alpha localization in the prefrontal cortex of three mammalian species.
        J Neuroendocrinol. 2008; 20: 893-903
        • Freeman E.W.
        • Rickels K.
        Characteristics of placebo responses in medical treatment of premenstrual syndrome.
        Am J Psychiatry. 1999; 156: 1403-1408
      2. European Medicines Agency. Guidelines on the treatment of PMDD. London. Available at: Accessed Feb. 18, 2013.

      3. Royal College of Obstetricians and Gynecologists. Management of premenstrual syndrome. RCOG green-top guideline no. 48, 2016. Available at: Accessed Jan. 13, 2017.

        • Shah N.R.
        • Jones J.B.
        • Aperi J.
        • Shemtov R.
        • Karne A.
        • Borenstein J.
        Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis.
        Obstet Gynecol. 2008; 111: 1175-1182
        • Andrade C.
        • Sharma E.
        Serotonin reuptake inhibitors and risk of abnormal bleeding.
        Psychiatr Clin North Am. 2016; 39: 413-426
        • Whelan A.M.
        • Jurgens T.M.
        • Naylor H.
        Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review.
        Can J Clin Pharmacol. 2009; 16: e407-e429
        • Blumenthal M.
        • Goldberg A.
        • Brinckmann J.
        Herbal medicine, expanded commission E monographs.
        Am Botanical Counc Integrative Med Commun. 2000; ( Accessed March 28, 2017): 62-64
        • Wuttke W.
        • Jarry H.
        • Christoffel V.
        • Spengler B.
        • Seidlová-Wuttke D.
        Chaste tree (Vitex agnus-castus)–pharmacology and clinical indications.
        Phytomedicine. 2003; 10: 348-357
        • Webster D.E.
        • He Y.
        • Chen S.N.
        • Pauli G.F.
        • Farnsworth N.R.
        • Wang Z.J.
        Opioidergic mechanisms underlying the actions of Vitex agnus-castus L.
        Biochem Pharmacol. 2011; 81: 170-177
        • Jarry H.
        • Spengler B.
        • Porzel A.
        • Schmidt J.
        • Wuttke W.
        • Christoffel V.
        Evidence for estrogen receptor beta-selective activity of Vitex agnus-castus and isolated flavones.
        Planta Med. 2003; 69: 945-947
      4. EMA. Community herbal monograph on Vitex agnus-castus L, fructus. London. Available at: Accessed Feb. 29, 2013.

        • Dante G.
        • Facchinetti F.
        Herbal treatments for alleviating premenstrual symptoms: a systemic review.
        J Psychosom Obstet Gynaecol. 2011; 32: 42-51
        • Van Die M.D.
        • Burger H.G.
        • Teede H.J.
        • Bone K.M.
        Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials.
        Planta Med. 2013; 79: 562-575
      5. Shaw S, Wyatt K, Campbell J, Ernst E, Thompson-Coon J. Vitex agnus castus for premenstrual syndrome (protocol). Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No: CD004632.

      6. Handbook for systematic reviews of interventions. Version 5.1.0. Cochrane Collaboration; 2011. Available at: Accessed March 28, 2017.

        • Egger M.
        • Davey Smith G.
        • Altman D.G.
        Systematic reviews in health care: meta-analysis in context.
        2nd ed. BMJ Publishing Group, London2001
        • Borenstein M.
        • Hedges L.
        • Higgins J.
        • Rothstein H.
        Comprehensive meta-analysis. Version 3.3.070.
        Biostat, Englewood (NJ)2005
        • Steiner M.
        • Haskett R.F.
        • Carroll B.J.
        Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales.
        Acta Psychiatr Scand. 1980; 62: 177-190
        • Moos R.H.
        The development of a menstrual distress questionnaire.
        Psychosom Med. 1968; 30: 853-867
        • Mortola J.F.
        • Girton L.
        • Beck L.
        • Yen S.S.
        Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences.
        Obstet Gynecol. 1990; 76: 302-307
      7. EndNote X6. 1988-2012. Version X6. London: Thomsom Reuters Scientific.

        • Cohen J.
        A coefficient for agreement for nominal scales.
        Educ Psychol Meas. 1960; 20: 37-46
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        PLoS Med. 2009; 6: e1000097
        • Liberati A.
        • Altman D.G.
        • Tetzlaff J.
        • et al.
        The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
        BMJ. 2009; 339: b2700
        • Harris R.J.
        • Bradburn M.J.
        • Deeks J.J.
        • Harbord R.M.
        • Altman D.G.
        • Sterne J.A.C.
        Metan: fixed- and random-effects meta-analysis.
        Stata J. 2008; 8: 3-28
      8. StataCorp. Stata: Release 13. StataCorp LP, College Station (TX)2013
        • Atmaca M.
        • Kumru S.
        • Tezcan E.
        Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder.
        Hum Psychopharmacol. 2003; 18: 191-195
        • Ciotta L.
        • Pagano I.
        • Stracquadanio M.
        • Di Leo S.
        • Andò A.
        • Formuso C.
        Aspetti psichici del disturb disforico della fase luteale: nuove prospettive terapeutiche, il Vitex agnus castus. Nostra esperienza.
        Minerva Ginecol. 2011; 63: 237-245
        • Delavar M.A.
        • Nasiri F.
        • Hoseini S.H.
        A double-blind placebo-controlled evaluation of Vitex agnus castus in premenstrual syndrome.
        J Med Plants. 2002; 1: 15-20
        • Di Pierro F.
        • Callegari A.
        • Speroni M.
        • Attolica M.
        Fast dissolving agnus castus fruit extract for the premenstrual syndrome. A controlled clinical trial.
        Nutrafoods. 2009; 8: 27-31
        • He Z.
        • Chen R.
        • Zhou Y.
        • et al.
        Treatment for premenstrual syndrome with Vitex agnus castus: a prospective, randomized, multi-center placebo controlled study in China.
        Maturitas. 2009; 63: 99-203
        • Kaplanoğlu M.
        • Aban M.
        Ethinyl estradiol-dropirenon versus Vitex agnus-castus extract in efficacy of the treatment of premenstrual syndrome.
        J Clin Anal Med. 2015; (Available at: Accessed March 28, 2017.)
        • Lauritzen C.H.
        • Reuter H.D.
        • Repges R.
        • Böhnert K.J.
        • Schmidt U.
        Treatment of premenstrual tension syndrome with Vitex agnus castus. Controlled, double-blind study versus pyridoxine.
        Phytomedicine. 1997; 4: 183-189
        • Mousavi P.
        • Zaheri H.
        • Najar S.
        • Afshari P.
        • Hayati F.
        Effect of vitagnus on premenstrual syndrome.
        Iran J Obstet Gynecol Infertil. 2015; 17: 1-9
        • Onaran Y.
        • Kurtay G.
        • Binici S.
        Premenstruël dönemde duygudurum. Premenstruël sendromda Vitex agnus castus ekstresi ve oral kantraseptiflerin duygudurum ϋzerindeki etkilerinin karsilastirilmasi.
        Kadin Dogum Dergisi. 2003; 2: 73-77
        • Pakgohar M.
        • Moradi M.
        • Jamshidi A.H.
        • Mehran A.
        Assessment of Vitex agnus-castus L. extract effect on treatment of premenstrual syndrome.
        J Med Plants. 2009; 8: 98-107
        • Risoleti E.V.I.
        • Giuffrida L.
        • Iozza I.
        • Garofalo O.
        • Valenti O.
        • Napoli C.
        Efficacia di Vitex agnus-castus nella sindroma premestruala: la nostra esperienza.
        G Ital Obstet Ginecol. 2011; XXXIII: 227-231
        • Salehi A.
        • Momeni H.
        • Seraji A.
        Comparison of the effects of Hypericum and Vitex agnus in premenstrual syndrome compared with vitamin E: a randomized clinical trial.
        Complementary Med J Faculty Nurs. 2013; 3: 41-53
        • Scaldarella L.O.
        • D'Ettore A.
        • Ciotola A.
        • Fusco G.
        • Ragucci V.
        • Colannino G.
        Utilizzo di Vitex agnus castus in pazienti con syndrome premestruale, mastodinia e iperprolattinemia.
        G Ital Obstet Ginecol. 2008; : 79-84
        • Schellenberg R.
        Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomized, placebo controlled study.
        BMJ. 2001; 322: 134-137
        • Schellenberg R.
        • Zimmermann C.
        • Drewe J.
        • Hoexter G.
        • Zahner C.
        Dose-dependent efficacy of the Vitex agnus castus extract ZE 440 in patients suffering from premenstrual syndrome.
        Phytomedicine. 2012; 19: 1325-1331
        • Turner S.
        • Mills S.
        A double-blind clinical trial on a herbal remedy for premenstrual syndrome: a case study.
        Complementary Ther Med. 1993; 1: 73-77
        • Zamani M.
        • Neghab N.
        • Torabian S.
        Therapeutic effect of Vitex agnus castus in patients with premenstrual syndrome.
        Acta Med Iran. 2012; 50: 101-106
        • Egger M.
        • Dickerson K.
        • Smith G.D.
        Problems and limitations in conducting systematic reviews.
        in: Egger M. Smith G.D. Altman D.G. Systematic reviews in health care. BMJ Publishing Group, London2001
        • Gagnier J.J.
        • Moher D.
        • Boon H.
        • Beyene J.
        • Bombardier C.
        Randomized controlled trials of herbal interventions underreport important details of the intervention.
        J Clin Epidemiol. 2011; 64: 760-769
        • Linde K.
        • Jonas W.B.
        • Melchart D.
        • Willich S.
        The methodological quality of randomized controlled trials of homeopathy, herbal medicines and acupuncture.
        Int J Epidemiol. 2001; 30: 526-531
        • Moher D.
        • Pham B.
        • Jones A.
        • et al.
        Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses?.
        Lancet. 1998; 352: 609-613
        • Schulz K.F.
        • Chalmers I.
        • Hayes R.J.
        • Altman D.G.
        Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.
        JAMA. 1995; 273: 408-412
        • Linde K.
        • Scholz M.
        • Ramirez G.
        • Clausius N.
        • Melchart D.
        • Jonas W.B.
        Impact of study quality on outcome in placebo-controlled trials of homeopathy.
        J Clin Epidemiol. 1999; 52: 631-636
        • Pittler M.H.
        • Abbot N.C.
        • Harkness E.F.
        • Ernst E.
        Location bias in controlled clinical trials of complementary/alternative therapies.
        J Clin Epidemiol. 2000; 53: 485-489
        • Ma L.
        • Lin S.
        • Chen R.
        • Zhang Y.
        • Chen F.
        • Wang X.
        Evaluating therapeutic effect in symptoms of moderate-to-severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women.
        Aust N Z J Obstet Gynaecol. 2010; 50: 189-193
        • Ma L.
        • Lin S.
        • Chen R.
        • Wang X.
        Treatment of moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women.
        Gynecol Endocrinol. 2010; 26: 612-616
        • Endicott J.
        • Nee J.
        • Harrison W.
        Daily Record of Severity of Problems (DRSP): reliability and validity.
        Arch Womens Ment Health. 2006; 9: 41-49
        • Gagnier J.J.
        • Boon H.
        • Rochon P.
        • Moher D.
        • Barnes J.
        • Bombardier C.
        Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration.
        J Clin Epidemiol. 2006; 59: 1134-1149